CN114502166A - 用卡博特韦和利匹韦林治疗hiv的方法 - Google Patents

用卡博特韦和利匹韦林治疗hiv的方法 Download PDF

Info

Publication number
CN114502166A
CN114502166A CN202080069721.1A CN202080069721A CN114502166A CN 114502166 A CN114502166 A CN 114502166A CN 202080069721 A CN202080069721 A CN 202080069721A CN 114502166 A CN114502166 A CN 114502166A
Authority
CN
China
Prior art keywords
salt
rilpivirine
cabotevir
administered
intramuscular injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080069721.1A
Other languages
English (en)
Chinese (zh)
Inventor
H.M.L.格劳韦尔斯
S.L.福德
D.A.马戈利斯
S.L.F.罗塞努
W.R.斯普林
R.M.范索林根-里斯泰亚
P.E.O.威廉姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
ViiV Healthcare Co
Original Assignee
Janssen Sciences Ireland ULC
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC, ViiV Healthcare Co filed Critical Janssen Sciences Ireland ULC
Priority to CN202410349180.8A priority Critical patent/CN118416069A/zh
Publication of CN114502166A publication Critical patent/CN114502166A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080069721.1A 2019-10-01 2020-10-01 用卡博特韦和利匹韦林治疗hiv的方法 Pending CN114502166A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410349180.8A CN118416069A (zh) 2019-10-01 2020-10-01 用卡博特韦和利匹韦林治疗hiv的方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962908995P 2019-10-01 2019-10-01
US201962908882P 2019-10-01 2019-10-01
US62/908,882 2019-10-01
US62/908,995 2019-10-01
US202063037782P 2020-06-11 2020-06-11
US63/037,782 2020-06-11
US202063052214P 2020-07-15 2020-07-15
US63/052,214 2020-07-15
PCT/IB2020/059185 WO2021064618A1 (en) 2019-10-01 2020-10-01 Method for treating hiv with cabotegravir and rilpivirine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410349180.8A Division CN118416069A (zh) 2019-10-01 2020-10-01 用卡博特韦和利匹韦林治疗hiv的方法

Publications (1)

Publication Number Publication Date
CN114502166A true CN114502166A (zh) 2022-05-13

Family

ID=72826936

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080069721.1A Pending CN114502166A (zh) 2019-10-01 2020-10-01 用卡博特韦和利匹韦林治疗hiv的方法
CN202410349180.8A Pending CN118416069A (zh) 2019-10-01 2020-10-01 用卡博特韦和利匹韦林治疗hiv的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410349180.8A Pending CN118416069A (zh) 2019-10-01 2020-10-01 用卡博特韦和利匹韦林治疗hiv的方法

Country Status (11)

Country Link
US (3) US20220347174A1 (enExample)
EP (1) EP4037661A1 (enExample)
JP (1) JP7791083B2 (enExample)
KR (1) KR20220074880A (enExample)
CN (2) CN114502166A (enExample)
AU (1) AU2020358156B2 (enExample)
CA (1) CA3155587A1 (enExample)
CL (1) CL2022000790A1 (enExample)
IL (1) IL290716A (enExample)
MX (1) MX2022003945A (enExample)
WO (1) WO2021064618A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103522C (en) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
WO2023222755A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
TW202408526A (zh) * 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(一)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573815A (zh) * 2009-09-22 2012-07-11 泰博特克药品公司 Hiv感染的治疗和预防
WO2019016732A1 (en) * 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS
CN109568328A (zh) * 2017-09-29 2019-04-05 重庆药友制药有限责任公司 一种用于预防和治疗hiv感染的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6319946B1 (en) 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
PT3366278T (pt) 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
CN104902905A (zh) 2012-12-14 2015-09-09 葛兰素史克有限责任公司 药物组合物
US20160067255A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
EA201790495A1 (ru) 2014-09-26 2017-09-29 Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед Фармацевтические композиции длительного действия
EP3986561B1 (en) * 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573815A (zh) * 2009-09-22 2012-07-11 泰博特克药品公司 Hiv感染的治疗和预防
WO2019016732A1 (en) * 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS
CN109568328A (zh) * 2017-09-29 2019-04-05 重庆药友制药有限责任公司 一种用于预防和治疗hiv感染的药物组合物

Also Published As

Publication number Publication date
JP7791083B2 (ja) 2025-12-23
CL2022000790A1 (es) 2022-11-25
AU2020358156B2 (en) 2024-06-06
IL290716A (en) 2022-04-01
EP4037661A1 (en) 2022-08-10
CN118416069A (zh) 2024-08-02
WO2021064618A1 (en) 2021-04-08
JP2022550828A (ja) 2022-12-05
US12636285B2 (en) 2026-05-26
US12636286B2 (en) 2026-05-26
US20220347174A1 (en) 2022-11-03
CA3155587A1 (en) 2021-04-08
AU2020358156A1 (en) 2022-04-21
US20250302829A1 (en) 2025-10-02
US20250302830A1 (en) 2025-10-02
MX2022003945A (es) 2022-04-25
KR20220074880A (ko) 2022-06-03

Similar Documents

Publication Publication Date Title
US20250339447A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20250302829A1 (en) Method for treating hiv with cabotegravir and rilpivirine
Llibre et al. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment
US11123329B1 (en) Use of angiotensin II type 2 receptor agonist
JP2025111701A (ja) 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド
Yu et al. Pharmacokinetic drug-drug interactions involving antiretroviral agents: an update
Andreoni et al. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project
TW201919586A (zh) 組合物及其用途和治療
WO2026050513A1 (en) Tolebrutinib for multiple sclerosis
BR112020000842A2 (pt) composições e métodos para tratamento do hiv
RU2840867C1 (ru) Способ лечения вич каботегравиром и рилпивирином
Pakyz et al. Overview of protease inhibitors
JP2020528413A (ja) Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
Raines et al. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks
US20220096487A1 (en) Methods for treating hiv with dolutegravir and lamivudine
Johnson et al. A systematic review of the use of atazanavir in women infected with HIV-1
Koren et al. Scientific basis of antiretroviral therapy
CA3268726A1 (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis
WO2014193589A1 (en) Cancer treatment method
Flamm Highlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting
Davies et al. Drug treatment of HIV and AIDS
Benzer et al. The current state of HIV therapy.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220513

WD01 Invention patent application deemed withdrawn after publication